ArticleBiochemistry2011
Structural and functional studies indicate that the EPEC effector, EspG, directly binds p21-activated kinase.
Article in Biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- α-Helices in the Type III Secretion Effectors: A Prevalent Feature with Versatile Roles.International journal of molecular sciences · 2021Review
- Molecular Mechanisms That Define Redox Balance Function in Pathogen-Host Interactions-Is There a Role for Dietary Bioactive Polyphenols?International journal of molecular sciences · 2019Review
- Article
- Modulation of epithelial cell polarity by bacterial pathogens.Annals of the New York Academy of Sciences · 2017Review
- Subverting Host Cell P21-Activated Kinase: A Case of Convergent Evolution across Pathogens.Pathogens (Basel, Switzerland) · 2017Review
- Inhibition of WAVE Regulatory Complex Activation by a Bacterial Virulence Effector Counteracts Pathogen Phagocytosis.Cell reports · 2016Article
- Enterohaemorrhagic E. coli modulates an ARF6:Rab35 signaling axis to prevent recycling endosome maturation during infection.Journal of molecular biology · 2016Article
- Tight Junction Disruption Induced by Type 3 Secretion System Effectors Injected by Enteropathogenic and Enterohemorrhagic Escherichia coli.Frontiers in cellular and infection microbiology · 2016Review
- Enteropathogenic E. coli: breaking the intestinal tight junction barrier.F1000Research · 2015Review
- Enteropathogenic E. coli effectors EspG1/G2 disrupt microtubules, contribute to tight junction perturbation and inhibit restoration.Cellular microbiology · 2014Article
- Enterohaemorrhagic Escherichia coli inhibits recycling endosome function and trafficking of surface receptors.Cellular microbiology · 2014Article
- Republished: tracing PAKs from GI inflammation to cancer.Postgraduate medical journal · 2014Article
- Effector triggered manipulation of host immune response elicited by different pathotypes of Escherichia coli.Virulence · 2014Review
- Actin cytoskeleton manipulation by effector proteins secreted by diarrheagenic Escherichia coli pathotypes.BioMed research international · 2013Review
- Enteropathogenic E. coli effectors EspG1/G2 disrupt tight junctions: new roles and mechanisms.Annals of the New York Academy of Sciences · 2012Review
- Manipulation of kinase signaling by bacterial pathogens.The Journal of cell biology · 2011Review
- Bacterial scaffolds assemble novel higher-order complexes to reengineer eukaryotic cell processes.Science signaling · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Bacterial pathogens secrete effectors into their hosts that subvert host defenses and redirect host processes. EspG is a type three secretion effector with a disputed function that is found in enteropathogenic Escherichia coli. Here we show that EspG is structurally similar to VirA, a Shigella virulence factor; EspG has a large, conserved pocket on its surface; EspG binds directly to the amino-terminal inhibitory domain of human p21-activated kinase (PAK); and mutations to conserved residues in the surface pocket disrupt the interaction with PAK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.